A von Willebrand factor fragment containing the D′D3 domains is sufficient to stabilize coagulation factor VIII in mice

Blood

Volumn 124, Issue 3, 2014, Pages 445-452

  Yee, Andrew ^a   Gildersleeve, Robert D ^a   Gu, Shufang ^b   Kretz, Colin A ^a   McGee, Beth M ^a   Carr, Keisha M ^a   Pipe, Steven W ^b   Ginsburg, David ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DIMER; IMMUNOGLOBULIN G1; MONOMER; VON WILLEBRAND FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHIMERA; CIRCULATION; DISULFIDE BOND; HUMAN; HUMAN CELL; HYDRODYNAMICS; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANIMALS; FACTOR VIII; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PEPTIDE FRAGMENTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; VON WILLEBRAND FACTOR;

EID: 84904512934     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-540534     Document Type: Article

References (55)

1. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404. (Pubitemid 8154146)
2. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160-174. (Pubitemid 30601459)
3. Nilsson IM, Blomback M, Blomback B. v. Willebrand's disease in Sweden; its pathogenesis and treatment. Acta Med Scand. 1959;164:263-278.
4. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol. 2012;87(Suppl 1):S33-S39.
5. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351(7):683-694.
6. Katsumi A, Tuley EA, Bodó I, Sadler JE. Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor. J Biol Chem. 2000;275(33):25585-25594.
7. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83(12):3536-3544. (Pubitemid 24175543)
8. Purvis AR, Gross J, Dang LT, et al. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc Natl Acad Sci USA. 2007;104(40):15647-15652. (Pubitemid 350035354)
9. Huang RH, Wang Y, Roth R, et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci USA. 2008;105(2):482-487. (Pubitemid 351171734)
10. Springer TA. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost. 2011;9(Suppl 1):130-143.
11. Vlot AJ, Koppelman SJ, Meijers JC, et al. Kinetics of factor VIII-von Willebrand factor association. Blood. 1996;87(5):1809-1816. (Pubitemid 26074100)
12. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem. 1997;272(29):18007-18014. (Pubitemid 27306379)
13. Lü J, Pipe SW, Miao H, Jacquemin M, Gilbert GE. A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function. Blood. 2011;117(11):3181-3189.
14. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262(18):8443-8446.
15. Hollestelle MJ, Lai KW, van Deuren M, et al. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS ONE. 2011;6(9):e24216.
16. Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction. J Biol Chem. 1991;266(21):13499-13502. (Pubitemid 21907376)
17. Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest. 1989;84(1):56-61. (Pubitemid 19170094)
18. Necina R, Amatschek K, Schallaun E, Schwinn H, Josic D, Jungbauer A. Peptide affinity chromatography of human clotting factor VIII. Screening of the vWF-binding domain. J Chromatogr B Biomed Sci Appl. 1998;715(1):191-201. (Pubitemid 28403611)
19. Jorieux S, Fressinaud E, Goudemand J, Gaucher C, Meyer D, Mazurier C. Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood. 2000;95(10):3139-3145. (Pubitemid 30321165)
20. Castro-Núñez L, Bloem E, Boon-Spijker MG, et al. Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII. J Biol Chem. 2013;288(1):393-400.
21. Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem. 1995;270(23):13826- 13833.
22. Saenko EL, Loster K, Josic D, Sarafanov AG. Effect of von Willebrand factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII. Thromb Res. 1999;96(5):343-354.
23. Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res. 2008;122(Suppl 4):S2-S8.
24. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270-279.
25. Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012;119(13):3024-3030.
26. Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013;121(11):2108-2116.
27. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA. 2002;99(15):10042-10047. (Pubitemid 34831169)
28. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell. 1999;96(1):111-120. (Pubitemid 29044158)
29. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325.
30. Lemmerhirt HL, Shavit JA, Levy GG, Cole SM, Long JC, Ginsburg D. Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene. Blood. 2006;108(9):3061-3067.
31. Marx I, Christophe OD, Lenting PJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112(3):603-609.
32. Pruss CM, Golder M, Bryant A, et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood. 2011;117(16):4358-4366.
33. Ott HW, Griesmacher A, Schnapka-Koepf M, et al. Analysis of von Willebrand factor multimers by simultaneous high- and low-resolution vertical SDS-agarose gel electrophoresis and Cy5-labeled antibody high-sensitivity fluorescence detection. Am J Clin Pathol. 2010;133(2):322-330.
34. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992;267(7):4424-4430.
35. De Meyer SF, Vandeputte N, Pareyn I, et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28(9):1621-1626.
36. Johnsen JM, Auer PL, Morrison AC, et al NHLBI Exome Sequencing Project. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood. 2013;122(4):590-597.
37. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279(13):12102-12109. (Pubitemid 38445774)
38. Mannucci PM, Kempton C, Millar C, et al; rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122(5):648-657.
39. Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost. 2014;40(1):17-27.
40. Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT. The RIIIS/J inbred mouse strain as a model for von Willebrand disease. Blood. 1990;76(11):2258-2265.
41. Desch KC, Ozel AB, Siemieniak D, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci USA. 2013;110(2):588-593.
42. Shavit JA, Manichaikul A, Lemmerhirt HL, Broman KW, Ginsburg D. Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice. Blood. 2009;114(26):5368-5374.
43. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood. 1995;85(11):3150-3157.
44. Casonato A, Sartorello F, Cattini MG, et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood. 2003;101(1):151-156. (Pubitemid 36025901)
45. Hilbert L, Nurden P, Caron C, et al INSERM Network on Molecular Abnormalities in von Willebrand Disease. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost. 2006;96(3):290-294. (Pubitemid 44377811)
46. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991;266(32):21948-21955. (Pubitemid 121000273)
47. Bendetowicz AV, Morris JA, Wise RJ, Gilbert GE, Kaufman RJ. Binding of factor VIII to von willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers. Blood. 1998;92(2):529-538. (Pubitemid 28323716)
48. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725. (Pubitemid 47327396)
49. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA. 2009;106(8):2788-2793.
50. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-2064.
51. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA. 2004;101(26):9763-9768. (Pubitemid 38869310)
52. Han KP, Zhu X, Liu B, et al. IL-15:IL-15 receptor alpha superagonist complex: high-level coexpression in recombinant mammalian cells, purification and characterization. Cytokine. 2011;56(3):804-810.
53. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666-672.
54. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol. 2004;5(2):121-132. (Pubitemid 38160255)
55. Dimitrov JD, Christophe OD, Kang J, et al. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. Biochemistry. 2012;51(20):4108-4116.